期刊文献+

尼达尼布在家兔体内的药动学研究 被引量:1

Study on Pharmacokinetics of Nintedanib in Rabbits
下载PDF
导出
摘要 目的:建立家兔血浆尼达尼布检测的高效液相色谱方法,研究尼达尼布在家兔体内的药动学。方法:采用ZORBAX SB-C18色谱柱为分离柱,以乙腈-0.1%三氟乙酸-水(35∶20∶45)为流动相,流速为1.0 ml·min^(-1),检测波长为286 nm,柱温为35℃;以卡马西平为内标,血浆在碱性条件下经乙酸乙酯萃取后检测。雄性家兔6只,按20 mg·kg^(-1)的剂量耳缘静脉注射给予尼达尼布;分别在给药前和给药后不同时间点耳缘静脉采集血液,分离血浆待测。用DAS 3.0计算药动学参数。结果:尼达尼布浓度在0.05~10.00μg·ml^(-1)范围内线性关系良好(r=0.999 8);低中高三个浓度(0.10,2.50,7.50μg·ml^(-1))的日内精密度RSD分别为5.55%、4.53%和2.74%,日间精密度RSD分别为6.15%、5.45%和3.15%;相对回收率分别为(98.50±5.47)%、(100.25±4.54)%和(99.94±2.74)%。6只家兔血浆尼达尼布浓度经DAS 3.0计算,尼达尼布的主要药动学参数如下:C_(max)为(3.01±0.35)μg·ml^(-1),t_(1/2)为(4.38±1.53)h,AUC_(0-t)为(11.67±1.71)μg·h·ml^(-1)。结论:该方法简便、快速、准确,适用于家兔血浆尼达尼布浓度的测定及其药动学研究。尼达尼布在家兔体内呈一级动力学消除。 Objective: To develop an HPLC method for the determination of nintedanib in rabbit plasma and study the pharmacokinetics of nintedanib in rabbits. Methods: The separation was performed on an Agilent ZORBAX SB-C18 column. A mixture of acetonitrile-0. 1% trifluoroacetic acid-water(35∶ 20 ∶ 45) was used as the mobile phase at a flow rate of 1. 0 ml · min(-1). The detection wavelength was set at 286 nm. Carbamazepine was used as the internal standard and nintedanib was extracted by ethyl acetate from plasma under basic condition. Totally 6 rabbits were given 20 mg·kg(-1)nintedanib with intravenous administration. The blood samples were collected from the auricular vein at different time points after the administration. The concentration of nintedanib in plasma was detected by the HPLC method. The pharmacokinetics parameters were analyzed by DAS program. Results: An excellent linear relationship was obtained within the range of 0. 05-10. 00 μg·ml(-1)(r = 0. 999 8). The intra-day RSD was 5. 55%,4. 53% and 2. 74%and inter-day RSD was 6. 15%,5. 45% and 3. 15%,respectively for the three concentrations(0. 10,2. 50 and 7. 50 μg·ml(-1)),and the relative recovery was(98. 50 ± 5. 47) %,(100. 25 ± 4. 54) % and(99. 94 ± 2. 74) %,respectively. The main pharmacokinetics parameters of nintedanib were as follows: C_(max)was(3. 01 ± 0. 35) μg·ml(-1),t_(1 /2)was( 4. 38 ± 1. 53) h and AUC_(0-t)was( 11. 67 ±1. 71) μg·h·ml(-1). Conclusion: The method is simple,rapid and accurate,and can be used to determine the nintedanib concentration in rabbit plasma and study its pharmacokinetics. Nintedanib is fitted the first-order elimination kinetics in rabbits.
出处 《中国药师》 CAS 2016年第3期453-455,共3页 China Pharmacist
关键词 尼达尼布 高效液相色谱法 血浆浓度 药动学 Nintedanib HPLC Plasma concentration Pharmacokinetics
  • 相关文献

参考文献9

  • 1Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy [ J]. Cancer Res, 2008 ;68:4774-4782.
  • 2Antoniu SA, Kolb MR. Nintedanib, a triple kinase inhibitor of VEG- FR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis[ J ]. IDrugs ,2010 ; 13:332-345.
  • 3Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-in- flammatory activity of the tyrosine kinaaeinhibitor nintedanib in exper- imental models of lung fibrosis[ J ]. J Phartru~l Exp Ther, 2014; 349:209-20.
  • 4Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nint- odanib in idiopathic pulmonary fibrosis[J]. N Engl J Med,2014; 370 : 2071-2082.
  • 5王茂湖,陈敏纯,李海燕,贾艳艳,周伦,丁莉坤,文爱东.吡非尼酮片在中国健康人体的药动学研究[J].中国药师,2013,16(1):40-43. 被引量:1
  • 6Tai WT,Shian CW,Li YS, ,et al. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity [J]. Journal of Hepatology , 2014 ; 61: 8 9-9 7.
  • 7Novello S,Kaiser R, Mellemgaard A, eta/. Analysis of patient-repor- ted outcomes from the LUME Lung 1 trial: A randomised, double- blind, placebo controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer [ J ]. European Journal of Cancer,2015 ; 51:317-326.
  • 8Capdevila J, Carrato A, Tabernero J, et al. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options forpatients with metastatic color- ectal cancer? [ J ]. Critical Reviews in Oncology/Hemataloffy,2014 ; 92:83-106.
  • 9马忠英,鹿成韬,宋薇,周伦,葛洁,李健康,李帆,丁莉坤,文爱东.LC-MS/MS法测定人血浆中尼莫地平浓度及其药动学研究[J].中国药师,2015,18(10):1689-1692. 被引量:2

二级参考文献16

  • 1王林,陈燕忠,汤祎.提高尼莫地平在注射液中溶解度的研究[J].广东药学院学报,2005,21(2):128-129. 被引量:1
  • 2朱胜平,彭向东,邹建军,程泽能,许树梧.高效液相色谱-质谱联用法研究两种尼莫地平制剂的生物等效性[J].中国医院药学杂志,2005,25(2):109-111. 被引量:7
  • 3王永升,赵小平,钟皎,陈燕,柳晓泉,王广基.HPLC-UV法测定比格犬血浆中吡非尼酮浓度及其药代动力学[J].中国药科大学学报,2006,37(2):146-149. 被引量:8
  • 4Shi S,Wu J,Chen H. Single-and multiple-dose pharmacokinetics of pirfenidone,an antifibrotic agent,in healthy Chinese volunteers[J].Journal of Clinical Pharmacology,2007,(10):1268-1276.
  • 5Azuma A,Taguchi Y,Ogura T. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment[J].BioMed Central Volume,2011,(01):143-153.
  • 6Noble PW,Albera C,Bradford WZ. Pirfenidone in patients with idiopathic pulmonary fibrosis(CAPACITY):two randomized trials[J].Lancet,2011,(9779):1760-1769.
  • 7Taniyama M,Ohbayashi S,Narita M. Pharmacokinetics of an antifibrotic agent,pirfenidone,in haemodialysis patients[J].European Journal of Clinical Pharmacology,1997,(01):77-78.
  • 8Rubino CM,Bhavnani SM,Ambrose PG. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults[J].Pulmonary Pharmacology and Therapeutics,2009.279-285.
  • 9戴幼琴,张瑜,鲁小峰,胡富强.尼莫地平纳米脂质微粒大鼠体内药动学及生物利用度研究[J].中国药学杂志,2007,42(24):1885-1887. 被引量:4
  • 10Qiu F, Ma YY, Wang YQ, et al. Determination of nimodipine in hu- man plasma by ultra performance liquid chromatography-tandem mass spectrometry and pharmacokinetic application [ J ]. J Pharm Biomed Anal, 2008, 46:557-562.

同被引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部